---
title: Autonomic Pharmacology
type: overview
phase: 1
status: complete
priority: high
tags: [autonomic, sympathetic, parasympathetic, adrenergic, cholinergic, neuromuscular, local-anesthetics]
created: 2025-11-08
last_modified: 2025-11-08
---

# Autonomic Pharmacology

## Overview

Autonomic pharmacology encompasses drugs that affect the autonomic nervous system (ANS), which controls involuntary physiological functions including heart rate, blood pressure, digestion, pupil size, and glandular secretion. Understanding autonomic pharmacology is fundamental to clinical practice as these drugs are used across virtually all medical specialties.

## Autonomic Nervous System Review

### Organization

**Sympathetic Nervous System (SNS)**:
- "Fight or flight" response
- Thoracolumbar outflow (T1-L2)
- Short preganglionic, long postganglionic neurons
- Neurotransmitters: Acetylcholine (preganglionic), Norepinephrine (postganglionic)
- Adrenal medulla releases epinephrine

**Parasympathetic Nervous System (PNS)**:
- "Rest and digest" response
- Craniosacral outflow (CN III, VII, IX, X; S2-S4)
- Long preganglionic, short postganglionic neurons
- Neurotransmitter: Acetylcholine (both preganglionic and postganglionic)

**Somatic Nervous System**:
- Voluntary motor control
- Neurotransmitter: Acetylcholine at neuromuscular junction

### Key Receptor Types

**Cholinergic Receptors**:
1. **Nicotinic** (ionotropic): Ganglia (Nn), NMJ (Nm)
2. **Muscarinic** (metabotropic): M1, M2, M3, M4, M5

**Adrenergic Receptors**:
1. **Alpha**: α1 (Gq), α2 (Gi)
2. **Beta**: β1, β2, β3 (all Gs)

**Dopaminergic Receptors**: D1-D5

## Subdirectory Contents

### 1. Sympathetic Drugs (Adrenergic Pharmacology)

**Sympathomimetics (Agonists)**:
- Direct agonists: Epinephrine, norepinephrine, isoproterenol
- Selective agonists: Phenylephrine (α1), clonidine (α2), dobutamine (β1), albuterol (β2)
- Indirect agonists: Amphetamine, cocaine, tyramine
- Mixed agonists: Ephedrine, pseudoephedrine

**Sympatholytics (Antagonists)**:
- α-blockers: Phentolamine, phenoxybenzamine, prazosin, doxazosin, tamsulosin
- β-blockers: Propranolol, metoprolol, atenolol, carvedilol, labetalol
- Mixed blockers: Labetalol, carvedilol

**Clinical Applications**:
- Cardiovascular: Hypertension, heart failure, arrhythmias, shock
- Respiratory: Asthma, COPD
- Ophthalmology: Glaucoma, mydriasis
- Urology: BPH, urinary retention
- Endocrine: Pheochromocytoma

### 2. Parasympathetic Drugs (Cholinergic Pharmacology)

**Cholinomimetics (Agonists)**:
- Direct agonists: Acetylcholine, bethanechol, carbachol, pilocarpine
- Indirect agonists (cholinesterase inhibitors):
  - Reversible: Neostigmine, physostigmine, pyridostigmine, donepezil, rivastigmine
  - Irreversible: Organophosphates, nerve agents

**Anticholinergics (Antagonists)**:
- Muscarinic antagonists: Atropine, scopolamine, ipratropium, tiotropium, oxybutynin, tolterodine
- Ganglionic blockers: Mecamylamine, trimethaphan (historical)

**Clinical Applications**:
- Gastrointestinal: Motility disorders, IBS
- Urinary: Overactive bladder, urinary retention
- Respiratory: COPD, asthma
- Ophthalmology: Cycloplegia, mydriasis
- Neurology: Myasthenia gravis, Alzheimer's disease
- Anesthesia: Antisialagogue, reversal of neuromuscular blockade
- Toxicology: Organophosphate poisoning

### 3. Neuromuscular Blockers

**Depolarizing Blockers**:
- Succinylcholine

**Non-Depolarizing Blockers**:
- Aminosteroids: Rocuronium, vecuronium, pancuronium
- Benzylisoquinolines: Atracurium, cisatracurium, mivacurium

**Reversal Agents**:
- Anticholinesterases: Neostigmine, edrophonium
- Sugammadex (rocuronium/vecuronium-specific)

**Clinical Applications**:
- Surgical anesthesia
- Endotracheal intubation
- Mechanical ventilation
- Electroconvulsive therapy

### 4. Local Anesthetics

**Ester Local Anesthetics**:
- Cocaine, procaine, benzocaine, tetracaine

**Amide Local Anesthetics**:
- Lidocaine, bupivacaine, ropivacaine, mepivacaine

**Clinical Applications**:
- Local/regional anesthesia
- Epidural/spinal anesthesia
- Nerve blocks
- Topical anesthesia
- Antiarrhythmic (lidocaine)

## Clinical Relevance

### Cardiovascular Medicine
- β-blockers: First-line for hypertension, heart failure, post-MI
- α-blockers: BPH, resistant hypertension
- β-agonists: Cardiogenic shock, bradycardia

### Pulmonary Medicine
- β2-agonists: Bronchodilation in asthma/COPD (albuterol, salmeterol)
- Anticholinergics: COPD management (ipratropium, tiotropium)

### Ophthalmology
- α-agonists: Glaucoma (brimonidine)
- β-blockers: Glaucoma (timolol)
- Muscarinic agonists: Glaucoma (pilocarpine)
- Anticholinergics: Mydriasis, cycloplegia

### Urology
- α-blockers: BPH (tamsulosin, alfuzosin)
- Anticholinergics: Overactive bladder (oxybutynin, tolterodine)
- Cholinergics: Urinary retention (bethanechol)

### Neurology
- Cholinesterase inhibitors: Myasthenia gravis (pyridostigmine), Alzheimer's (donepezil)

### Anesthesiology
- Neuromuscular blockers: Intubation, surgery
- Local anesthetics: Regional/local anesthesia
- Anticholinergics: Antisialagogue (glycopyrrolate)

### Emergency Medicine
- Epinephrine: Anaphylaxis, cardiac arrest
- Atropine: Bradycardia, organophosphate poisoning
- β-blockers: Hypertensive emergency (labetalol)

## Key Concepts

### Receptor Selectivity
- **Selective drugs**: Fewer off-target effects, better tolerated
- **Non-selective drugs**: More side effects but broader applications
- Examples: β1-selective (metoprolol) vs. non-selective (propranolol)

### Tissue Distribution
- Different tissues express different receptor subtypes
- Explains drug specificity and side effects
- Example: β1 (heart) vs. β2 (lungs, vessels)

### Signal Transduction
- **Gs (β, α2)**: cAMP pathway
- **Gi (α2)**: Inhibit cAMP
- **Gq (α1, M1, M3)**: IP3/DAG, Ca2+ mobilization
- **Ionotropic (nicotinic)**: Direct ion channel opening

### Sympathetic vs. Parasympathetic Balance
- Most organs have dual innervation
- Opposing effects maintain homeostasis
- Drugs shift balance in therapeutic direction

## Clinical Pearls

1. **α1 vs. α2**: α1 → vasoconstriction; α2 (presynaptic) → decreased NE release
2. **β1 vs. β2**: β1 → heart (1 heart); β2 → lungs (2 lungs)
3. **Muscarinic effects**: SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis)
4. **Atropine uses**: Bradycardia, organophosphate poisoning, antisialagogue
5. **Succinylcholine**: Only depolarizing blocker; causes fasciculations, hyperkalemia
6. **Esters vs. Amides**: Esters metabolized by plasma esterases (allergy risk); amides by liver
7. **Non-selective β-blockers contraindicated in asthma**: Block β2 → bronchoconstriction
8. **α-blocker side effects**: Orthostatic hypotension, reflex tachycardia
9. **Cholinergic crisis vs. myasthenic crisis**: Both weakness; differentiate with edrophonium
10. **Local anesthetic toxicity**: CNS (seizures) then cardiovascular (arrhythmias, arrest)

## Exam Focus

### High-Yield Topics
1. Receptor selectivity and tissue distribution
2. Mechanism of action for each drug class
3. Clinical uses: When to use which drug
4. Adverse effects and contraindications
5. Drug interactions (especially β-blockers)
6. Autonomic physiology review
7. Antidote knowledge (atropine, physostigmine, sugammadex)
8. Anaphylaxis treatment (epinephrine)
9. Neuromuscular blocker reversal
10. Local anesthetic systemic toxicity

### Common Question Types
- Match receptor to physiological effect
- Predict side effects from receptor activity
- Choose appropriate drug for clinical scenario
- Identify contraindications
- Reversal agents for toxicity/overdose
- Mechanism-based questions

## Integration with Other Topics

### Physiology
- Cardiovascular physiology (baroreceptor reflex)
- Respiratory physiology (bronchodilation)
- Renal physiology (sympathetic effects)

### Pathology
- Pheochromocytoma (catecholamine excess)
- Myasthenia gravis (NMJ dysfunction)
- Autonomic neuropathy (diabetes)

### Clinical Medicine
- Hypertension management
- Heart failure treatment
- COPD/asthma therapy
- BPH management
- Perioperative medicine

## Summary

Autonomic pharmacology forms a cornerstone of clinical therapeutics. Mastery requires understanding:
1. Autonomic nervous system organization and physiology
2. Receptor types, locations, and signal transduction
3. Drug mechanisms (agonist vs. antagonist, direct vs. indirect)
4. Clinical applications across specialties
5. Adverse effects and contraindications
6. Drug interactions and special populations

## Key Takeaways

1. **Sympathetic drugs** affect α and β adrenergic receptors
2. **Parasympathetic drugs** affect muscarinic and nicotinic receptors
3. **Receptor selectivity** determines therapeutic uses and side effects
4. **β-blockers** are mainstay of cardiovascular medicine
5. **β2-agonists** are first-line for asthma/COPD
6. **Anticholinergics** treat overactive bladder, COPD
7. **Cholinesterase inhibitors** treat myasthenia gravis, Alzheimer's
8. **Neuromuscular blockers** essential for anesthesia
9. **Local anesthetics** enable regional/local procedures
10. **Emergency drugs**: Epinephrine (anaphylaxis), atropine (bradycardia, OP poisoning)

---

**Study Approach**: Master receptor physiology first, then drug mechanisms, then clinical applications. Practice clinical scenarios to reinforce learning.

**Clinical Application**: These drugs are among the most commonly prescribed. Understanding their pharmacology is essential for safe, effective practice across all medical specialties.
